These findings suggest that in the breast cancer TME, the upregulation of PAX5 during the transformation of NFs into CAFs enhances PRKCQ-AS1 expression, which subsequently mediates tamoxifen resistance in ER + breast cancer cells. Here, PRKCQ is linked to breast carcinoma.